November 16, 2026 Global Pulse

Nuclear Medicine Radioisotope Supply Is the Quiet Bottleneck in Oncology

By Isabelle Fontaine | Senior Analyst, Cross-Sector Equity & Market Intelligence
8 min read

The growth of nuclear medicine as a clinical discipline, accelerated by the commercial success of theranostic radiopharmaceuticals and the expanding use of PET imaging across oncology staging and treatment monitoring, is running into a supply constraint that receives far less attention than the clinical and commercial milestones of approved radiopharmaceutical products: the production infrastructure for the medical radioisotopes that make these therapies and imaging agents possible is fragile, geographically concentrated, and in several critical cases operating at capacity utilisation levels that leave essentially no buffer against unplanned outages at the handful of research reactors and cyclotrons that supply the global clinical market. The dependency of nuclear medicine on isotope production infrastructure that includes decades-old research reactors operated by national nuclear agencies, a small number of commercial isotope producers who have invested in modern processing and distribution capabilities, and a cold chain logistics network whose reliability determines whether short-lived isotopes reach patient care in usable form creates supply chain risk that the clinical and commercial success of radiopharmaceuticals is now exposing in ways that were manageable when nuclear medicine was a niche specialty but are becoming commercially significant as it scales toward mainstream oncology practice.

Molybdenum-99 and the Technetium-99m Dependency

Technetium-99m, the daughter isotope of molybdenum-99 with a six-hour half-life that makes it the workhorse of diagnostic nuclear medicine used in approximately 40 million procedures annually worldwide, is produced at a small number of research reactors that have experienced serial unplanned outages over the past two decades that created global shortages affecting patient care at hospitals dependent on Tc-99m-based cardiac, bone, and renal imaging. The NRU reactor in Chalk River Canada, the HFR reactor in Petten Netherlands, and the BR2 reactor in Mol Belgium have historically supplied the majority of global Mo-99, and coordinated outage management through the OECD Nuclear Energy Agency's High-level Group on the Security of Supply of Medical Radioisotopes has improved supply reliability relative to the crisis periods of 2009 and 2010, but the fundamental vulnerability of depending on aging research reactor infrastructure for a clinically essential diagnostic isotope has not been resolved by coordination alone. The commercial response to this structural vulnerability includes investments in accelerator-based Mo-99 production that does not depend on reactor neutron flux, with SHINE Medical Technologies in Wisconsin and NorthStar Medical Radioisotopes in Wisconsin having developed commercial-scale accelerator and neutron-capture Mo-99 production that provides supply diversification beyond the reactor-dependent supply chain that created past shortages.

The economics of Mo-99 production and distribution are complicated by the isotope's 66-hour half-life that requires production, processing, distribution, and generator loading to occur within a tightly managed weekly cycle, with technetium generators shipped from processing facilities to hospital radiopharmacies on a schedule calibrated to deliver usable Tc-99m activity within the clinical use window. Curium, Eckert and Ziegler, and GE Healthcare's radiopharmacy network are among the commercial entities managing the Mo-99 to Tc-99m generator supply chain whose operational complexity and capital requirements create barriers to entry that limit the number of commercial participants and sustain the supply concentration that creates clinical risk.

Lutetium-177 and the Theranostic Isotope Buildout

Lutetium-177, the beta-emitting therapeutic isotope used in Novartis's Lutathera for neuroendocrine tumours and Pluvicto for PSMA-positive prostate cancer, has seen demand grow dramatically following Pluvicto's 2022 FDA approval and the expansion of PSMA theranostic treatment to commercial scale, creating supply constraints that Novartis publicly acknowledged were limiting patient access to Pluvicto in the period following approval and driving investment in Lu-177 production capacity that the global isotope industry is working to expand. The production of Lu-177 requires neutron irradiation of lutetium-176 enriched targets in research reactors at sufficient neutron flux to achieve the specific activity required for clinical use, and the number of reactors globally with the combination of neutron flux, target handling infrastructure, and hot cell processing capability required for Lu-177 production at clinical scale is limited to a handful of facilities including the HFIR reactor at Oak Ridge National Laboratory, the BR2 reactor in Belgium, and commercial reactor facilities in Russia, South Africa, and India. BWXT Medical, Eckert and Ziegler, ITG Isotope Technologies, and Niowave are investing in expanded Lu-177 production capacity in North America and Europe to address the supply constraint and reduce dependence on non-Western production facilities for a therapeutic isotope whose clinical demand is growing at rates that require production capacity investment decisions to be made years before the clinical demand materialises.

Actinium-225 and the Next Isotope Supply Challenge

Actinium-225, the alpha-emitting isotope whose daughter bismuth-213 delivers targeted alpha therapy in PSMA and other theranostic applications with a cytotoxic potency per decay event meaningfully greater than beta emitters like Lu-177, has a global production capacity of approximately 2 to 3 curies annually from its primary sources including the decay of uranium-233 stockpiles at Oak Ridge National Laboratory and Dimitrovgrad in Russia, a quantity that is fundamentally insufficient to supply the clinical trial programmes currently evaluating Ac-225 labelled radiopharmaceuticals, let alone the commercial demand that would result from regulatory approval of one or more Ac-225 therapies. The Ac-225 supply constraint is widely recognised in the radiopharmaceutical industry as the binding constraint on the development of targeted alpha therapy as a commercial treatment modality, and the investment in alternative Ac-225 production pathways including linear accelerator bombardment of radium-226 targets at TRIUMF in Canada, ORNL, and BNL, as well as cyclotron-based production approaches, represents the most urgent infrastructure challenge in medical isotope supply for the next decade of nuclear medicine development.

Top 10 Companies in Medical Isotopes and Nuclear Supply Chain

  1. Curium -- Global nuclear medicine company with Mo-99 production, Tc-99m generator manufacturing, and radiopharmaceutical development across diagnostic and therapeutic isotopes, with European and North American production and distribution infrastructure serving hospital radiopharmacies.
  2. Eckert and Ziegler -- German isotope technology company with Lu-177, Ga-68, and specialty isotope production alongside radiopharmaceutical development services, serving the growing theranostic radiopharmaceutical manufacturing market across Europe and internationally.
  3. SHINE Medical Technologies -- Wisconsin-based accelerator-based Mo-99 producer providing reactor-independent supply diversification for the global Tc-99m generator market, with commercial-scale production capacity addressing the structural vulnerability of reactor-dependent Mo-99 supply chains.
  4. BWXT Medical -- Canadian medical isotope producer with Lu-177 and Mo-99 production capabilities, investing in expanded North American therapeutic isotope manufacturing capacity for the growing theranostic radiopharmaceutical market.
  5. Novartis Radioligand Therapy -- Pharmaceutical company commercialising Lutathera and Pluvicto Lu-177 theranostic therapies, with significant investment in radiopharmaceutical manufacturing scale-up at its Millburn New Jersey and international facilities to address Pluvicto supply constraints.
  6. ITG Isotope Technologies -- German Lu-177 and specialty isotope producer with reactor-based production capabilities supplying clinical-grade therapeutic isotopes to radiopharmaceutical manufacturers across Europe and North America.
  7. NorthStar Medical Radioisotopes -- Wisconsin-based accelerator and neutron capture Mo-99 producer with domestic US supply capability for Tc-99m generators, providing supply chain resilience for the US hospital nuclear medicine market.
  8. GE Healthcare (Radiopharmacy) -- Medical technology company with radiopharmacy network supplying unit dose Tc-99m radiopharmaceuticals and other diagnostic isotopes to hospitals across North America, managing Mo-99 sourcing and generator operations at commercial scale.
  9. TRIUMF -- Canadian national particle physics laboratory with Ac-225 production development programme using proton beam irradiation of radium-226 targets, representing one of the primary alternative production pathways for the alpha therapy isotope whose supply constraint limits targeted alpha therapy development.
  10. Lantheus Holdings -- US radiopharmaceutical company with PYLARIFY Ga-68 PSMA PET imaging agent and pipeline of diagnostic and therapeutic radiopharmaceuticals, with manufacturing and distribution infrastructure serving the growing clinical market for precision oncology nuclear medicine.

Our Take

Medical isotope supply is the infrastructure story that the radiopharmaceutical industry's commercial success is making impossible to ignore, as the gap between the clinical and commercial demand that approved theranostic products are generating and the production capacity available to supply them is a real constraint on patient access and market growth rather than a theoretical risk that forward planning can keep manageable. The Lu-177 supply situation following Pluvicto's approval demonstrated that isotope supply chain investment decisions made years before regulatory approval are insufficient when the commercial uptake of an approved product exceeds the market's capacity forecast, and the lesson for the Ac-225 ecosystem is that production infrastructure investment needs to begin well ahead of the first alpha therapy approval rather than in response to it. The commercial opportunity for isotope producers who build production capacity ahead of demand is real and durable, as the specificity of reactor and cyclotron infrastructure requirements and the regulatory qualification timelines for new isotope sources create competitive moats that sustained demand will reward. For pharmaceutical companies building theranostic pipelines, isotope supply security is now a drug development risk that deserves the same rigour as clinical and manufacturing risk management rather than being treated as a procurement challenge to be addressed after regulatory approval. -- Elena Vasquez, MarketsNXT

Back to All Insights
×